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ABSTRACT 
Background. Clinical trials have established the average benefit of cardiac 
resynchronization therapy (CRT), but estimating benefit for individual patients remains 
difficult because of the heterogeneity in treatment response. Accordingly, we created a 
multivariable model to predict changes in quality of life (QoL) with and without CRT. 
Methods. Patient-level data from 5 randomized trials comparing CRT with no 
CRT were used to create a prediction model of change in QoL at 3 months using a partial 
proportional odds model for no change, small, moderate and large improvement or 
deterioration of any magnitude. The c-statistics for not worsening or obtaining at least a 
small, moderate, and large improvement were calculated.   
Results.  Among the 3614 patients, regardless of assigned treatment, 33.3% had a 
deterioration in QoL, 9.2% had no change, 9.2% had a small improvement, 13.5% had a 
moderate improvement, and the remaining 34.9% had a large improvement. Patients 
undergoing CRT were less likely to have a decrement in their QoL (28.2% vs. 38.9%, 
p<0.001) and more likely to have a large QoL improvement (38.7% vs. 30.6%, p<0.001). 
A partial proportional odds model identified baseline QoL, age, and an interaction of 
CRT with QRS duration as predictors of QoL benefits 3 months after randomization. C-
statistics of 0.65 for not worsening, 0.68 for at least a small improvement, 0.69 for at 
least a moderate improvement, and 0.73 for predicting a large improvement were 
observed.  
Conclusions. There is marked heterogeneity of treatment benefit of CRT that can 
be predicted based upon baseline QoL, age and QRS duration.   
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Introduction 
For patients with advanced systolic heart failure and a widened QRS, guidelines 
recommend several therapies, including cardiac resynchronization therapy (CRT), to 
improve survival and quality of life (QoL).
1, 2
 It is inherently difficult, however, to apply 
guidelines to individual patients whose benefits from treatment may differ substantially 
from the ‘average’ benefit described in clinical trials. This issue is of particular concern 
for CRT, which requires a relatively complex, expensive, invasive procedure compared to 
a pharmacological therapy that can easily be given for a trial period and easily withdrawn 
if it causes problems. Also, the response to CRT is heterogeneous, some patients improve 
while others worsen. In general, patients are 8-10% more likely to experience a favorable 
improvement in disease specific quality of life with vs. without CRT.
3-6
 
Previous efforts to create risk models to personalize the estimated benefits of CRT 
have focused on survival.
7
 Importantly, such models do not inform patients and their 
providers of the likely benefits of CRT on the patient’s QoL.3 Given the importance of 
QoL to patients,
8
 formally modeling the heterogeneity of treatment benefit for QoL 
outcomes can assist physicians in patient selection, enable more accurate discussions of 
the risks and benefits of treatment and  support shared medical decision-making.
9-11
 To 
address the need for a tool to individualize treatment based upon anticipated QoL benefits 
for individual patients, we used patient-level data from 5 randomized trials of CRT to 
develop a multivariable risk prediction model of QoL benefit after CRT. 
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METHODS 
Data Source.  Patient-level data were pooled from 5 randomized controlled trials 
of CRT therapy and included 4317 patients. Details of the CARE-HF, MIRACLE, 
MIRACLE-ICD, REVERSE, and RAFT studies have been described previously.
3, 4, 12-14
 
Each trial was approved by an institutional review board and informed consent was 
obtained. The pooled data set was completely deidentified and considered non-human 
subjects research. While there were differences among the trials, all included adult 
patients with a diagnosis of chronic heart failure, left ventricular dysfunction, and a wide 
QRS complex. All trials had at least 6 months of follow-up and collected disease-specific 
health status data at baseline and follow-up. Given the paucity of data on patients with 
New York Heart Association (NYHA) class I, we restricted the analyses to those with 
NYHA II-IV.  
Health Status Measures.  Disease-specific health status was assessed in the trials 
using the Minnesota living with heart failure (MLWHF) and Kansas City 
Cardiomyopathy questionnaire (KCCQ).
15, 16
 The MLWHF was collected in all 5 trials, 
while the KCCQ were collected only in REVERSE. The MLWHF contains 21 questions 
and has a range in overall scores of 0-105 points, with lower scores indicating better QoL. 
The KCCQ is a 12- or 23-item instrument that ranges in overall scores from 0-100 points, 
where higher scores indicate better health status.
17
 Both instruments have been shown to 
be reliable, responsive, and valid measures of patients’ heart failure symptoms, functional 
status, and disease-specific QoL. However, the data for interpreting what constitutes 
clinically important changes in overall score has been more clearly defined for the 
KCCQ,
18
 where a 5-, 10-, and 20-point change in the KCCQ Overall Summary score 
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corresponds to a small, moderate, and large clinical change in patients’ health status.8, 18, 
19
   
Selecting the time for modeling health status benefits.  Given the variability in 
the timing of QoL collection amongst the trials, we needed to define a suitable time for 
modeling follow-up health status. The most QoL data were available at 3 months 
(Appendix Table S1). However, to ensure that 3 months was a sufficient length of time 
for the QoL benefits of CRT to be attained, we evaluated the change in QoL from 
baseline to 3, 6 and 12 months. For the MLWHF, across all patients, there was a mean 
improvement of -12.4 from baseline to 3 months. At 6 months, the mean MLWHF 
change from baseline was -12.7, with no significant difference between the changes from 
baseline at month 3 and month 6, (p-value 0.10); Appendix Figure S1). We therefore 
selected the 3-month health status assessment to model the heterogeneity of treatment 
benefit from CRT. To evaluate the models performance on longer-term outcomes, a 
sensitivity analysis evaluating calibration and discrimination was conducted on patients 
with 12 month QoL data available.  
Defining Clinically Important Changes in QoL.  To improve the clinical 
interpretability of the models and support their use in patient selection and shared 
decision-making, we sought to model clinically important categories of change, rather 
than modeling the MLWHF as a continuous score. Given that there are much clearer 
thresholds to interpret the magnitude of change that is clinically important with the 
KCCQ, we modeled the improvement in the MLWHF associated with small, moderate or 
large improvements in KCCQ scores.
18, 19
 To perform this analysis, we used data from 
REVERSE, which simultaneously collected both the MLWHF and KCCQ. Changes in 
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KCCQ from baseline to 3 months suggested that a small clinical improvement in the 
MLWHF questionnaire was -6.67 points; a moderate improvement was -10.41 points; 
and a large clinical improvement was -17.90 points (Supplemental S1).  
Statistical Analyses.  As particular patients may find different levels of change in 
QoL clinically relevant, we used a cumulative logit model to estimate the heterogeneity 
of treatment benefit with CRT. This cumulative logit model can be thought of as an 
extension of the logistic regression model that applies to dichotomous dependent 
variables, allowing for more than two (ordered) response categories. It uses cumulative 
probability up to a possible threshold, thereby making the whole range of ordinal 
categories binary at that particular threshold. In this study, we used 4 cutoff points for 
MLWHF change from baseline at 3 months (-2.92 reflecting deterioration, <-6.67 for a 
small QoL improvement, <-10.41 for a moderate QoL improvement, and -17.9 for a large 
QoL improvement). The cumulative logit model thus enables the estimation of the 
probabilities that a patient will be worse (>-2.92 points), unchanged (-2.92 to -6.67 
points), slightly (-6.67 to -10.4 points), moderately (-10.4 to -17.9 points) or substantially 
better (<-17.9 points) at 3 months.  
Candidate variables were selected a priori on the basis of published literature and 
clinical experience and included: age, sex, angiotensin converting enzyme inhibitors 
(ACE-I) or angiotensin II receptor blockers (ARB), beta-blockers, left ventricular 
ejection fraction (LVEF), left ventricular end diastolic dimension, diabetes, QRS duration, 
left bundle branch block (LBBB), MLWHF at baseline, CRT, atrial rhythm, and ischemic 
etiology of cardiomyopathy. Spironolactone use and NYHA class at baseline were both 
highly collinear with baseline QoL and thus omitted as candidate variables. Interactions 
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between CRT and other variables were examined and retained if statistically significant. 
We used stepwise variable selection to select the final variables for the model. The 
assumption of linearity was assessed for each continuous variable with the use of 
restricted cubic splines. The proportional odds assumptions were tested for all variables 
included in the final model, and assumptions held for all variables except baseline QoL, 
requiring separate intercepts for each category of 3-month QoL change. To take into 
clustering of patients by study, study was included a random effect.   
Discrimination (c statistic) was calculated for each binary cumulative outcome at 
each threshold of clinical change.  In sensitivity analysis, calibration plots were 
created by comparing observed versus predicted probability by decile of no change,  
small improvement, moderate improvement, and large improvements in QoL. 
Statistical analyses were conducted with SAS version 9.3 (SAS Institute, Cary, NC) and 
R version 2.7.2. 
 
RESULTS 
Study Population.  Of the 4317 patients from the 5 trials, 98 patients were 
excluded as they died prior to the 3-month QoL assessment (censored at end of 
randomization period). Patients not surviving to 3-months were older, with a worse QoL 
and generally sicker at baseline (Supplemental table S2). We also excluded patients 
without baseline (n=117) or 3-month QoL data (n= 388), and excluded the patients with 
NYHA class 1 (n= 100), leaving 3614 patients for this analysis, of whom 1890 were 
assigned to CRT. Patients excluded for missing QoL data had better baseline QoL and 
were more likely to be on a beta blocker, however, other baseline characteristics were 
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similar to the analytic cohort (Supplemental table S3).  Mean age of the cohort was 
6510 years, 78% were men, 30% had diabetes, and 58% had an ischemic 
cardiomyopathy. Mean LVEF was 246%, mean QRS duration was 16224 ms, and 76% 
had a left bundle branch block (LBBB). Mean MLWHF at baseline was 42.423.4. 
Baseline characteristics between CRT and controls were generally well balanced with the 
exception of more patients in the CRT cohort being NYHA II (52.2% vs. 48.3%, p = 
0.017) and on beta blockers (80.3% vs. 76.7%, p = 0.008) (Supplemental table S4).  
Change in QoL and CRT Effect.  Among the 3614 patients, regardless of 
assigned treatment, 33.3% had deterioration in QoL, 9.2% had no change, 9.2% had a 
small improvement, 13.5% had a moderate improvement, and the remaining 34.9% had a 
large improvement. The baseline characteristics of patients, stratified by change in QoL, 
are presented in Table 1. From baseline to 3 months, the MLWHF score improved, on 
average, by -14.0 ± 20.6 with CRT vs. -10.3 ± 20.8 with optimal medical therapy (OMT) 
for a mean difference of 3.7 points (p<0.001), which is less than the estimated minimally 
important difference of  -6.67 points. However, there was considerable heterogeneity in 
response (Figure 1). For patients in NYHA III or IV at baseline (n=1795), the mean 
difference between CRT and OMT was -6.3 (p < 0.0001) points but for those in NYHA II 
(n=1819), it was only -1.5 points (p = 0.10). In a responder analysis, which categorizes 
patients’ changes in QoL into worse (>-2.92 points), unchanged (-2.92 to 6.67 points), 
slightly (-6.67 to -10.4 points), moderately (-10.4 to -17.9 points) or substantially better 
(<-17.9 points), patients undergoing CRT were less likely to have a decrement in their 
QoL (28.2% vs. 38.9%, p<0.001) and more likely to have a large QoL improvement 
(38.7% vs. 30.6%, p<0.001; Supplemental Table 5).  These differences were more 
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marked in patients who were in NYHA III or IV at baseline compared to those in NYHA 
II, respectively (Figure 2a and 2b).  
Predictors of QoL Improvement.  The partial proportional odds model 
identified baseline QoL, age, and an interaction of CRT with QRS duration as significant 
predictors of improvement in QoL at 3 months. (Figure 3). Patients with wider QRS 
duration had the greatest benefit from CRT. Worse baseline QoL and older age were 
associated with more improvement at 3 months, regardless of treatment. Baseline QoL 
had different risks for different magnitudes of clinical change, but overall the lower the 
baseline health status, the greater likelihood of a large improvement in QoL over 3 
months' follow-up, regardless of CRT. The discrimination (c-statistics) of the partial 
proportional odds model for not worse, at least small improvement, at least moderate 
improvement, and large improvement were 0.65, 0.68, 0.69, and 0.73, respectively.  A 
sensitivity analysis of the models performance among subjects with 12-month QoL data 
available was conducted. At 12-months the model had better discrimination with c-
statistics of 0.71, 0.74, 0.76 and 0.79 for not worse, at least small improvement, at least 
moderate improvement, and large improvement, respectively, and demonstrated excellent 
calibration (see Figures S2-S5) 
Figure 4 demonstrates a potentially actionable output format for these models 
when used at the bedside for clinical decision making. In this example, a 72-year old with 
a baseline MLWHF of 52 and QRS duration of 175 ms would have a 54% probability of 
a large QOL improvement with CRT as compared to 33% without CRT (NNT = 5). 
Conversely a 35-year-old with a baseline MLWHF of 40 and QRS duration of 130 would 
have only a 36% probability of a large improvement with CRT vs. 31% without CRT 
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(NNT = 20).  
 
DISCUSSION 
Despite the undoubted benefits of CRT, there are concerns that it has been 
underused in clinical practice, with only about a third of eligible patients being treated.
20, 
21
 More appropriate use of CRT has been estimated to potentially save more than 8,000 
lives per year in the USA alone.
21
 A potential reason for the underuse of CRT is the 
difficulty in weighing the risks and benefits the procedure for a specific patient. While a 
substantial amount of work has been done to try to understand which patients will 
respond to CRT, benefit has been measured in terms of echocardiographic response or a 
reduction in morbid or fatal events, despite the fact that patients may care more about the 
quality of their lives than its quantity.
22
  To extend prior reports of the average QoL 
benefits of CRT in a study population, we developed a method for personalizing the 
estimated likelihood of QoL improvement with CRT. Such a model could support more 
evidence-based, patient-centered care by helping patients and their providers understand 
the benefits that they might expect from CRT, especially when coupled with a model 
estimating the CRT benefits on survival.
7
 
Our findings extend prior investigations of the QoL benefits of CRT, which have 
shown increasing survival with longer QRS duration and in those with more severe heart 
failure but have not been able to clearly define patient characteristics associated with 
improved QoL.
4, 7, 23, 24
 Our analysis found that after adjusting for QRS duration, QRS 
morphology does not predict the response to CRT, consistent with two prior patient level 
analyses 
14, 25
 but not another.
26
 It is notable that the majority of patients (76%) in our 
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analysis had LBBB, and it is possible that those with wide right bundle branch block 
(RBBB) had some underlying left sided dyssynchrony, so extrapolation to those with 
pure RBBB may be limited. Also contrary to some previous analyses
27, 28
, gender was not 
predictive of QoL improvement in the final multivariable model, despite women deriving 
more benefit in unadjusted analyses. We hypothesize that this is due to the worse QoL 
scores in women at the time of treatment and that once baseline QoL was accounted for 
gender was no longer independently associated with CRT benefit. Moreover, we found 
that baseline QoL was very important, where worse baseline health status was associated 
with a greater likelihood of improvement. Older patients obtained greater benefit in QoL, 
despite prior studies showing less use of CRT in older patients.
29
 Using a coarser 
assessment of QoL than the MLQHF questionnaire, the NYHA classification, we found 
more benefit in those with NYHA III/IV as compared to those with NYHA II.  
Clinical Implications.  Our data provide an opportunity to estimate the QoL 
benefits for an individual patient and to use this information, coupled with mortality and 
peri-procedural risks, to engage patients in shared decision-making about CRT.
7, 30
 While, 
our tool only assesses the initial benefits of CRT it is reassuring that the model continued 
to perform well at 12 month post implant.  Further work will be needed to define  
strategies for optimizing CRT in order to maximize QoL improvement, and to define the 
longer-term QoL benefits of treatment.  
Potential Limitations. Our decision to include a patient reported outcome (PRO) into the 
model as opposed to more commonly available NYHA class may hinder implementation. 
Our rationale to include MLHWF (or PROs in general) as opposed to NYHA class is that 
the later is a very crude measurement and subject to ‘gaming’. There have been several 
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articles explicitly demonstrating low inter-rater reliability of the NYHA with a 
concordance between 2 different cardiologists’ assessments of the same patient of about 
0.54.
31-33
 In contrast, the intra-class correlation of health status questionnaires, such as the 
KCCQ, are quite high with a an estimate of ~0.92 in stable patients.
34
  Further 
underscoring the value of collecting PRO data is the accuracy of the model when a more 
detailed, reproducible assessment of health status is used. For these reasons, we believe 
that the improved accuracy of the models is greater and justifies the added burden of 
collecting patients’ health status with a questionnaire. 
  Our findings should be considered in the context of several potential limitations. 
QoL change from baseline to 3 months was used as our endpoint since the largest amount 
of follow up QoL data was available at 3 months and most of the QoL benefit occurred 
within this timeframe. In sensitivity analysis the model performed well at 12 months, 
however, there was not an opportunity to explore longer-term outcomes that may have 
been associated with greater QoL benefits, which might be particularly relevant in 
patients with NYHA II. This will require future research with longer-term outcomes, 
which may be important given the evidence of continuing positive remodeling of the left 
ventricle up to 18 months after CRT implantation.
35, 36
 Second, as there are not well-
developed thresholds of clinical change for the MLHFQ, we had to model these 
thresholds based upon the clinically-important thresholds of change defined by the 
KCCQ. We used linear regression from patients with simultaneous MLHFQ and KCCQ 
in REVERSE to estimate clinical meaningful thresholds in MLFHQ because much more 
work has been conducted to define clinically important thresholds of change in the 
KCCQ than the MLHFQ. While we conducted sensitivity analyses and found consistent 
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results, this methodology hasn’t been validated in other datasets and REVERSE included 
healthier patients than many CRT trials. Future efforts to better map the MHLFQ to the 
KCCQ could validate our estimates and might change, presumably modestly, the results 
of our model by using a different threshold of clinically significant change.  Third, we 
used older CRT studies, which could impact generalizability of our findings to current 
practice, as our model may underestimate the benefits of CRT with newer, more 
advanced devices (quadripolar leads, multi-point pacing, adaptive CRT, etc.). While 
these evolutions in technology may underestimate the benefits of CRT, it is also possible 
that evolving medical therapies may have improved the health status of patients not 
treated with CRT. Thus, these models should be considered an initial step in an evolving 
effort to validate and improve patient-specific outcome estimates. Fourth, the controls 
groups of the pooled data were not identical, while MIRACLE, MIRACLE-ICD, 
REVERSE, and RAFT had devices implanted, but turned off, CARE had only medical 
therapy. It is thus possible that the greater QoL benefit in CARE may have reflected a 
placebo effect, further underscoring the value of including all trials in our analyses. Fifth, 
while independent patient data was available, certain lab values and information about 
peripheral artery disease, lung disease, and ICD shocks (appropriate and inappropriate) 
were not available to be included in the model. Finally, our model has not been validated 
in other RCTs or in registries and external validation of these models should be pursued.  
Conclusion.  We identified substantial variability in the benefits of CRT on QoL, 
which could be modeled using only 3 variables, age, baseline health status and QRS 
duration. This model may contribute to the infrastructure for personalizing the benefits of 
CRT for those being considered for this intervention. Future studies should examine 
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whether the prospective use of this and models that predict procedural risks and long-
term morbidity and mortality can improve patients’ participation in shared decision-
making, target the use of CRT to patients most likely to benefit, and whether this 
approach to precision medicine can enhance the ability of this important technology to 
improve the outcomes of patients with heart failure.   
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FIGURE LEGEND 
 
Figure 1. Individual patient’s baseline (X axis), and 3 month (Y axis) Minnesota 
Living With Heart Failure overall score after being assigned to receive cardiac 
resynchronization therapy. Yellow shaded area represents patients with significant 
improvement in quality of life. Blue shaded area represents patients with significant 
worsening in quality of life. 
 
Figure 2a Clinically meaningful changes in quality of life of CRT versus control 
amongst NYHA II patients. 
 
Figure 2b. Clinically meaningful changes in quality of life of CRT versus control 
amongst NYHA III patients. 
 
Figure 3. Association of patient characteristics with magnitude of Quality Life 
Change at 3-months based on partial proportion odds model.  
 
Figure 4. Example model output for patient shared decision making. Predicted risk 
estimates are depicted with bars; lines represent 95% confidence intervals. NICM 
indicates non-ischemic cardiomyopathy; LBBB indicates left bundle branch block, 
RBBB indicates right bundle branch block.  
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Table 1.  Baseline Characteristics by Change in Quality of Life at 3 Months 
  
Deterioration 
n=1203 
No Change 
n=332 
Small 
Improvement 
n=331 
Moderate 
Improvement 
n=488 
Large 
Improvement 
n=1260 
p-value 
Age (y) 65.5 ± 10.3 66.6 ± 9.8 65.6 ± 10.2 64.1 ± 10.8 64.7 ± 10.1 0.004 
Male 977 (81.2%) 273 (82.2%) 262 (79.2%) 378 (77.5%) 937 (74.4%) <0.001 
QRS width (ms) 161 ± 24 161 ± 23 163 ± 24 164 ± 24 163 ± 24 0.061 
Left bundle branch block 73.7% 76.1% 78.2% 76.5% 76.6% 0.349 
Cardiac resynchronization therapy 44.3% 53.6% 54.4% 54.7% 58.1% <0.001 
Implantable defibrillator 65.1% 67.5% 66.2% 64.1% 65.9% 0.878 
NYHA Class       
II 620 (51.5%) 201 (60.5%) 186 (56.2%) 251 (51.4%) 561 (44.5%) < 0.001 
III 554 (46.1%) 125 (37.7%) 137 (41.4%) 222 (45.5%) 647 (51.3%) 
 
IV  29 (2.4%) 6 (1.8%) 8 (2.4%) 15 (3.1%) 52 (4.1%) 
 
Left ventricular ejection fraction 
(%) 
24.2 ± 6.1 24.5 ± 6.3 24.2 ± 6.6 24.1 ± 6.1 23.6 ± 6.1 0.024 
Systolic blood pressure (mmHg) 118.4 ± 18.1 119.3 ± 18.5 119.5 ± 17.5 117.8 ± 17.6 117.1 ± 17.7 0.083 
Ischemic cardiomyopathy 703 (58.4%) 204 (61.4%) 187 (56.5%) 257 (52.7%) 749 (59.4%) 0.066 
Diabetes mellitus 30.8% 30.0% 28.6% 28.4% 30.1% 0.901 
MLWHF at baseline  31.6 ± 21.1 31.8 ± 22.6 37.5 ± 22.1 42.6 ± 21.7 56.6 ± 18.7 <0.001 
ACE-I/ARB 1152 (95.8%) 317 (95.5%) 316 (95.5%) 467 (95.7%) 1193 (94.7%) 0.760 
Beta blocker 935 (77.7%) 285 (85.8%) 261 (78.9%) 384 (78.7%) 976 (77.5%) 0.018 
Spironolactone 43.9% 40.6% 38.7% 48.3% 43.9% 0.080 
Values are shown as absolute numbers (percentages), mean ± SD. NYHA, New York Heart Association; MLWHF, Minnesota Living 
with Heart Failure; ACE-I, angiotensin converting enzyme-inhibitor; ARB, angiotensin II receptor blocker
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Figure 1. Individual patient’s baseline (X axis), and 3 month (Y axis) Minnesota Living With Heart Failure overall score after 
being assigned to receive cardiac resynchronization therapy (a) and medical therapy (b). 
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Figure 2a. Responder analysis of quality of life change form baseline to 3 months by NYHA II patients (a) and NYHA 
III/IV patients (b).  
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Figure 3.  Forest plot of Odds Ratios from partial proportion odds model (higher scores in MLWHF indicate a worse quality 
of life) 
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MLWHF = Minnesota Living With Heart Failure; CRT = cardiac resynchronization therapy; MM = medical therapy.  
QRS Width (+10 ms) among OMT pts
QRS Width (+10 ms) among CRT pts
CRT vs OMT among pts with QRS Width 180 ms
CRT vs OMT among pts with QRS Width 161 ms
CRT vs OMT among pts with QRS Width 145 ms
Age (+10 years)
     OR for at least no change per +5 units
     OR for at least small improvement per +5 units
     OR for at least moderate improvement per +5 units
     OR for large improvement per +5 units
Baseline MLWHF (pts with scores above median):
     OR for at least no change per +5 units
     OR for at least small improvement per +5 units
     OR for at least moderate improvement per +5 units
     OR for large improvement per +5 units
Baseline MLWHF (pts with scores below median):
Odds Ratio (95% CI)
0.5 1 1.5 2 2.5
0.99 (0.94, 1.05)
1.07 (1.02, 1.13)
1.84 (1.48, 2.30)
1.59 (1.33, 1.90)
1.42 (1.14, 1.77)
1.10 (1.00, 1.20)
1.23 (1.19, 1.26)
1.27 (1.23, 1.30)
1.30 (1.26, 1.34)
1.33 (1.29, 1.38)
1.30 (1.22, 1.38)
1.37 (1.29, 1.46)
1.42 (1.33, 1.51)
1.45 (1.35, 1.56)
Odds Ratios: Cumulative logit model
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Figure 4. Example model output for patient shared decision making. *Estimates of mortality taken from Cleland et al “An 
individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and 
mortality in patients with symptomatic heart failure.”7 
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